Overview

NCI Definition: A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. The nuclear features which characterize the thyroid gland papillary carcinoma are absent. Radiation exposure is a risk factor and it comprises approximately 10% to 15% of thyroid cancers. Clinically, it usually presents as a solitary mass in the thyroid gland. It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels. Diagnostic procedures include thyroid ultrasound and fine needle biopsy. [1]

Thyroid gland follicular carcinomas most frequently harbor alterations in NRAS, TP53, TBX3, PTEN, and HRAS [2].

Most Commonly Altered Genes in Thyroid Gland Follicular Carcinoma

NRAS Mutation (somatic), NRAS Mutation (germline), NRAS Mutation, NRAS Codon 61 Missense, and NRAS Q61R are the most common alterations in thyroid gland follicular carcinoma [2].

Top Alterations in Thyroid Gland Follicular Carcinoma

Significant Genes in Thyroid Gland Follicular Carcinoma

BRAF +

ERBB2 +

HRAS +

KRAS +

NRAS +

Disease Details

Synonyms
Follicular Adenocarcinoma, Follicular Thyroid Cancer, Follicular Carcinoma of the Thyroid, Follicular Cancer of Thyroid Gland, Follicular Carcinoma of the Thyroid Gland, Follicular Cancer of the Thyroid Gland, CARCINOMA, FOLLICULAR CELL, MALIGNANT, Follicular Carcinoma, Well-Differentiated Follicular Carcinoma, Well-differentiated Follicular Adenocarcinoma, Follicular Cancer of Thyroid, Follicular Cancer of the Thyroid
Parent(s)
Well-Differentiated Thyroid Gland Carcinoma
Children
Thyroid Gland Oncocytic Follicular Carcinoma
OncoTree Name
Follicular Thyroid Cancer
OncoTree Code
THFO

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.